United Therapeutics (NASDAQ:UTHR) Upgraded at Raymond James Financial

Raymond James Financial upgraded shares of United Therapeutics (NASDAQ:UTHR) to a moderate buy rating in a report issued on Thursday,Zacks.com reports.

Other analysts have also issued research reports about the stock. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $486.00 to $575.00 and gave the company an “equal weight” rating in a research report on Tuesday, March 31st. Bank of America boosted their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Oppenheimer boosted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Cantor Fitzgerald boosted their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Finally, TD Cowen boosted their price target on shares of United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research report on Monday, March 30th. Ten analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $601.50.

United Therapeutics Trading Down 0.5%

Shares of United Therapeutics stock opened at $571.73 on Thursday. The company has a market cap of $25.06 billion, a PE ratio of 20.49, a price-to-earnings-growth ratio of 1.65 and a beta of 0.75. United Therapeutics has a 1-year low of $272.12 and a 1-year high of $607.89. The company has a 50 day moving average of $516.68 and a 200-day moving average of $484.65.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period in the previous year, the company earned $6.19 earnings per share. Research analysts forecast that United Therapeutics will post 24.48 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $565.87, for a total transaction of $4,696,721.00. Following the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $25,561,479.64. This represents a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $580.45, for a total transaction of $5,514,275.00. Following the sale, the chief executive officer directly owned 40,513 shares in the company, valued at $23,515,770.85. This trade represents a 19.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 387,270 shares of company stock valued at $199,027,180. Company insiders own 10.30% of the company’s stock.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Avoro Capital Advisors LLC increased its holdings in United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the period. Wellington Management Group LLP increased its holdings in United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. AQR Capital Management LLC increased its holdings in United Therapeutics by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after acquiring an additional 295,221 shares during the period. Janus Henderson Group PLC increased its holdings in United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after acquiring an additional 341,383 shares during the period. Finally, Darwin Global Management Ltd. bought a new stake in United Therapeutics during the 3rd quarter worth approximately $317,617,000. Institutional investors own 94.08% of the company’s stock.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Raymond James initiated/covered UTHR with an “outperform” rating and a $700 price target, implying roughly ~22% upside from the recent price — a material bullish catalyst for sentiment and valuing upside. Read More.
• Positive Sentiment: Morgan Stanley raised its price target on UTHR to $519 (from $471), signaling incremental analyst confidence in the shares and helping underpin the stock. Read More.
• Neutral Sentiment: Short‑interest data in the recent report show effectively zero reported short interest (appears anomalous/immaterial), so short‑squeeze dynamics are not a current driver. (Data point reported publicly.)
• Negative Sentiment: CFO James Edgemond sold 10,000 shares (~$5.78M) on April 9 at an average $577.89; the sale was part of a Rule 10b5‑1 plan but reduces his direct stake by ~34.6% — multiple recent 10b5‑1 sales by the CFO may be viewed negatively by some investors. Read More.
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares (~$5.51M) on April 8 at an average $580.45 under a pre‑arranged 10b5‑1 plan; while planned sales limit immediate governance concern, the size and timing add selling weight to headlines. Read More.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.